OA12774A - Controlled synthesis of ziprasidone and compositions thereof. - Google Patents

Controlled synthesis of ziprasidone and compositions thereof. Download PDF

Info

Publication number
OA12774A
OA12774A OA1200400216A OA1200400216A OA12774A OA 12774 A OA12774 A OA 12774A OA 1200400216 A OA1200400216 A OA 1200400216A OA 1200400216 A OA1200400216 A OA 1200400216A OA 12774 A OA12774 A OA 12774A
Authority
OA
OAPI
Prior art keywords
composition
dihydro
indol
ziprasidone
chloro
Prior art date
Application number
OA1200400216A
Other languages
English (en)
Inventor
Frank Robert Busch
Adam Worth Grobin
Howard Harry Ralph Jr
Kyle Robert Leeman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12774(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA12774A publication Critical patent/OA12774A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
OA1200400216A 2002-02-20 2003-02-17 Controlled synthesis of ziprasidone and compositions thereof. OA12774A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35880602P 2002-02-20 2002-02-20
US35903802P 2002-02-21 2002-02-21
US36045902P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
OA12774A true OA12774A (en) 2006-07-04

Family

ID=27761437

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400216A OA12774A (en) 2002-02-20 2003-02-17 Controlled synthesis of ziprasidone and compositions thereof.

Country Status (41)

Country Link
EP (1) EP1476162B1 (sr)
JP (1) JP4554938B2 (sr)
KR (1) KR100773622B1 (sr)
CN (2) CN1635892A (sr)
AP (1) AP2004003103A0 (sr)
AR (1) AR038563A1 (sr)
AT (1) ATE359787T1 (sr)
AU (2) AU2003206035A1 (sr)
BR (1) BR0307833A (sr)
CA (1) CA2475302C (sr)
CO (1) CO5611138A2 (sr)
CY (1) CY1106467T1 (sr)
DE (1) DE60313289T2 (sr)
DK (1) DK1476162T3 (sr)
EA (1) EA007866B1 (sr)
EC (1) ECSP045239A (sr)
ES (1) ES2283745T3 (sr)
GE (1) GEP20074030B (sr)
GT (1) GT200300040A (sr)
HR (1) HRP20040711A2 (sr)
IL (1) IL163277A (sr)
IS (1) IS7344A (sr)
MA (1) MA27177A1 (sr)
MX (1) MXPA04006993A (sr)
MY (1) MY139523A (sr)
NO (2) NO20043902L (sr)
NZ (1) NZ534443A (sr)
OA (1) OA12774A (sr)
PA (1) PA8567001A1 (sr)
PE (1) PE20030942A1 (sr)
PL (1) PL372238A1 (sr)
PT (1) PT1476162E (sr)
RS (1) RS60404A (sr)
SI (1) SI1476162T1 (sr)
SV (1) SV2004001485A (sr)
TN (1) TNSN04159A1 (sr)
TW (1) TW200307546A (sr)
UA (1) UA77057C2 (sr)
UY (1) UY27668A1 (sr)
WO (1) WO2003070246A1 (sr)
ZA (1) ZA200406276B (sr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101230034A (zh) 2000-03-06 2008-07-30 阿卡蒂亚药品公司 用于治疗5-羟色胺相关性疾病的氮杂环化合物
NZ571695A (en) 2001-12-28 2010-02-26 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
CA2490397A1 (en) 2002-06-24 2003-12-31 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
US7601740B2 (en) 2003-01-16 2009-10-13 Acadia Pharmaceuticals, Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
WO2004083192A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd. Polymorphis of valsartan
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
EP1546146A1 (en) 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
US20050197347A1 (en) * 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
DE602005018171D1 (de) 2004-02-27 2010-01-21 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
BRPI0516063A (pt) 2004-09-27 2008-08-19 Acadia Pharm Inc sìntese de n-(4-fluorbenzil)-n-(1-metilpiperidin-4-il)-n'-(4-(2-metilp ropi-loxi)fenilmetil)carbamida e seu sal tartarato e formas cristalinas
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
US20090163513A1 (en) * 2005-01-27 2009-06-25 Hetero Drugs Limited Process for ziprasidone using novel intermediates
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN100491375C (zh) * 2006-07-01 2009-05-27 浙江美诺华药物化学有限公司 一种齐拉西酮的制备方法
EP2134330B1 (en) 2007-03-19 2013-05-08 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
CN102234272A (zh) * 2010-04-21 2011-11-09 上海医药工业研究院 盐酸齐拉西酮半水合物的制备方法
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US11464768B2 (en) 2016-12-20 2022-10-11 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
CN108239085A (zh) * 2016-12-26 2018-07-03 四川科瑞德凯华制药有限公司 一种甲磺酸齐拉西酮的纯化及制备方法
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN112724066B (zh) * 2021-02-04 2022-10-21 海南鑫开源医药科技有限公司 一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) * 2023-01-17 2023-05-02 北京协和建昊医药技术开发有限责任公司 一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
PT874834E (pt) 1995-11-07 2001-04-30 Pfizer Processos e intermediarios para preparacao de 3-(1-piperazinil)-1,2-benzisotiazole
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
ATE236902T1 (de) * 1996-05-07 2003-04-15 Pfizer Mesylat des trihydrats des 5-(2-(4-(1,2- benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor 1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
TW200307546A (en) 2003-12-16
JP4554938B2 (ja) 2010-09-29
CO5611138A2 (es) 2006-02-28
IS7344A (is) 2004-07-05
AP2004003103A0 (en) 2004-09-30
ES2283745T3 (es) 2007-11-01
NO20100584L (no) 2004-09-17
PL372238A1 (en) 2005-07-11
ECSP045239A (es) 2004-09-28
CN101735212A (zh) 2010-06-16
AU2003206035A1 (en) 2003-09-09
UY27668A1 (es) 2003-10-31
CA2475302A1 (en) 2003-08-28
EP1476162A1 (en) 2004-11-17
TNSN04159A1 (fr) 2007-03-12
GEP20074030B (en) 2007-02-12
MXPA04006993A (es) 2004-11-10
MA27177A1 (fr) 2005-01-03
SI1476162T1 (sl) 2007-08-31
IL163277A (en) 2010-05-31
PE20030942A1 (es) 2003-11-08
WO2003070246A1 (en) 2003-08-28
EA200400815A1 (ru) 2004-12-30
UA77057C2 (en) 2006-10-16
RS60404A (sr) 2006-10-27
SV2004001485A (es) 2004-05-07
PA8567001A1 (es) 2003-12-10
AU2009202008A1 (en) 2009-06-11
ZA200406276B (en) 2005-09-20
KR20040086417A (ko) 2004-10-08
DE60313289D1 (de) 2007-05-31
NZ534443A (en) 2007-07-27
CN1635892A (zh) 2005-07-06
JP2005525347A (ja) 2005-08-25
KR100773622B1 (ko) 2007-11-05
GT200300040A (es) 2007-01-12
NO20043902L (no) 2004-09-17
HRP20040711A2 (en) 2004-12-31
CY1106467T1 (el) 2012-01-25
PT1476162E (pt) 2007-06-25
DK1476162T3 (da) 2007-07-02
AR038563A1 (es) 2005-01-19
MY139523A (en) 2009-10-30
BR0307833A (pt) 2004-12-07
CA2475302C (en) 2009-05-12
DE60313289T2 (de) 2007-12-27
ATE359787T1 (de) 2007-05-15
EA007866B1 (ru) 2007-02-27
EP1476162B1 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
OA12774A (en) Controlled synthesis of ziprasidone and compositions thereof.
US5021421A (en) 2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
DE69918278T2 (de) Substituierte indolalkansäure
EP3197867B1 (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
US20040048876A1 (en) Ziprasidone composition and synthetic controls
JP2020503298A (ja) 単環式ｏｇａ阻害剤化合物
KR19990066852A (ko) 정신병 증상의 치료방법
CN103228643B (zh) 作为组胺h4受体配体的苯并唑衍生物
JP2002536291A (ja) ２−（４−アリール又はヘテロアリール−ピペラジン−１−イルメチル）−１ｈ−インドール誘導体
MXPA06001229A (es) Derivados de 1-sulfonilindol, su preparacion y su uso como ligandos de 5-ht6.
EP4125910B1 (en) Rho kinase inhibitors for treating frontotemporal dementia
JPH09512542A (ja) Ｄ▲下４▼リセプタ拮抗剤としてのベンゾフラン誘導体
JPH11508280A (ja) 三環式アミノアルキルカルボキサミド；新規なドーパミンｄ▲下３▼受容体サブタイプに特異的なリガンド
CN1355800A (zh) 噻唑烷二酮衍生物及其作为抗糖尿病药的用途
US20040242642A1 (en) Crystalline esomeprazole compounds and process for the preparation thereof
CN106146504B (zh) 一种杂环并咪唑类化合物、其药物组合物及其制备方法和用途
KR100621249B1 (ko) 투렛증후군을치료하기위한약학조성물
EP3810594A1 (en) Oga inhibitor compounds
JP4557112B2 (ja) ベンゾオキサゾール誘導体及び該誘導体を有効成分として含む医薬
IL293929A (en) Oga inhibitor compounds
RU2155765C2 (ru) Производные 1,4-дигидропиридина с циклическим мостиком в положениях 1,2 в форме смеси их изомеров
SK51052006A3 (sk) Pyridínové deriváty alkyloxindolov ako aktívne látky voči 5-HT7 receptoru
WO2025233532A1 (en) Maxi-k potassium channel openers and therapeutic applications thereof
KR20240006657A (ko) 염색체 2, 2:107,510,000-107,540,000 유전자좌에서 단일 뉴클레오티드 다형성을 갖는 대상체를 진단 및 치료하는 방법
JPS63165368A (ja) 新規複素環化合物およびその製造法